Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Weisel Initiates Coverage of Waters

NEW YORK (GenomeWeb News) – Investment bank Thomas Weisel Partners has initiated coverage of Waters with an "overweight" rating on the firm's stock.

Analyst Peter Lawson wrote in a research note Thursday that Waters received an "overweight" rating because of three factors: its "industry-leading position in the life science space with industry high operating margins; its better-than-peer execution on earnings growth, organic revenue growth, and earnings consistency; and its discount valuation versus both peers and historical levels."

According to the research note, Waters' product breadth and its position as a market share leader in liquid chromatography and top-three player in mass spectrometry means it is well positioned if pharma companies cut down on the number of suppliers they use for research equipment.

"Despite the near-term uncertainty surrounding pharmaceutical R&D spending, the company appears well positioned over the intermediate and long term, and we are attracted to the near-term valuation," Lawson wrote.

He placed a 12-month price target of $63 on Waters' shares, which closed down 1 percent at $55.09 in Thursday trade on the New York Stock Exchange.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.